Trasylol Linked To Increased Long-Term Mortality In CABG Patients – JAMA
Executive Summary
Bayer's Trasylol (aprotinin) is associated with an increased risk of death in the five years following coronary artery bypass graft surgery (CABG), according to a study published in the Feb. 7 Journal of the American Medical Association